Development of a population pharmacokinetic model for the novel long-acting injectable antipsychotic risperidone ISM®.
Christian LaveilleEric SnoeckLourdes Ochoa Díaz de MonasteriogurenJavier Martínez-GonzálezJordi LlaudóLourdes AntaIbon GutierroPublished in: British journal of clinical pharmacology (2024)
The population PK model adequately described active moiety concentrations from five clinical studies after risperidone ISM® administration. Relationships between active moiety exposure and covariates were defined in order to facilitate simulations for future studies. The model showed that risperidone ISM® rapidly achieves therapeutic plasma levels within the first hours after the first injection that are maintained sustainedly throughout the whole dosing interval following once-monthly gluteal injections of 100 mg and 75 mg.